DOCSLIB.ORG

A Duplication in the Canine ß-Galactosidase Gene GLB1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Duplication in the Canine ß-Galactosidase Gene GLB1 Copyright © 2005 by the Genetics Society of America DOI: 10.1534/genetics.105.042580 A Duplication in the Canine ␤-Galactosidase Gene GLB1 Causes Exon Skipping and GM1-Gangliosidosis in Alaskan Huskies Robert Kreutzer,* Tosso Leeb,†,1 Gundi Mu¨ller,* Andreas Moritz‡ and Wolfgang Baumga¨rtner* *Department for Pathology and †Department for Animal Breeding and Genetics, University of Veterinary Medicine, 30559 Hannover, Germany and ‡Clinic for Small Animals, Internal Medicine, Justus Liebig University, 35392 Giessen, Germany Manuscript received February 25, 2005 Accepted for publication April 28, 2005 ABSTRACT GM1-gangliosidosis is a lysosomal storage disease that is inherited as an autosomal recessive disorder, predominantly caused by structural defects in the ␤-galactosidase gene (GLB1). The molecular cause of GM1-gangliosidosis in Alaskan huskies was investigated and a novel 19-bp duplication in exon 15 of the GLB1 gene was identified. The duplication comprised positions ϩ1688–ϩ1706 of the GLB1 cDNA. It partially disrupted a potential exon splicing enhancer (ESE), leading to exon skipping in a fraction of the transcripts. Thus, the mutation caused the expression of two different mRNAs from the mutant allele. One transcript contained the complete exon 15 with the 19-bp duplication, while the other transcript lacked exon 15. In the transcript containing exon 15 with the 19-bp duplication a premature termination codon (PTC) appeared, but due to its localization in the last exon of canine GLB1, nonsense-mediated RNA decay (NMD) did not occur. As a consequence of these molecular events two different truncated GLB1 proteins are predicted to be expressed from the mutant GLB1 allele. In heterozygous carrier animals the wild-type allele produces sufficient amounts of the active enzyme to prevent clinical signs of disease. In affected homozygous dogs no functional GLB1 is synthesized and GM1-gangliosidosis occurs. HE canine lysosomal acidic ␤-galactosidase (GLB1, cally active ␤-galactosidase (D’Azzo et al. 1982; Bous- TEC 3.2.1.23) is an exoglycosidase that removes tany et al. 1993). The significance of the 22- to 24-kDa ␤-ketosidically linked galactose residues from glycopro- C-terminal GLB1 domain, encoded partially by exons teins, sphingolipids, and keratan sulfate (van der Spoel 15 and 16, is supported by the identification of several et al. 2000). GM1 -gangliosidosis is a lysosomal storage amino acid substitutions in different forms of GM1 -gan- disease, inherited as an autosomal recessive disorder, gliosidosis in canine (Wang et al. 2000; Yamato et al. predominantly caused by structural defects in the ␤-galac- 2002) and human patients (Boustany et al. 1993; Mor- tosidase gene (GLB1)(Thomas and Beaudet 1995; Cal- rone et al. 2000; van der Spoel et al. 2000). lahan 1999). Mutations in the GLB1 gene were identi- Many disease-associated mutations affect pre-mRNA fied in Portuguese waterdogs with GM1 -gangliosidosis splicing, usually causing incorrect exon assembly (Wang et al. 2000) and in Shiba inus with GM1 -ganglio- (Cartegni et al. 2002). Up to 15% of point mutations sidosis (Yamato et al. 2002). The GLB1 gene is located responsible for genetic diseases in humans cause aber- on chromosome 3p21 in humans (NCBI MapViewer, rant splicing (Krawczak et al. 1992). The most common human genome build 35.1) and on chromosome 23 in consequence of these mutations is exon skipping. In dog (Priat et al. 1998; Breen et al. 2001). Both ortholo- constitutive splicing all exons are included in the mature gous GLB1 genes contain 16 exons and share 86.5% mRNA, whereas in the skipped pattern one or more identity at the nucleotide level and 81% identity at the exons are missing. The regulation of this process is still amino acid level (Wang et al. 2000). In both species not very well understood; so far, cis-regulatory elements GLB1 is synthesized as an 85-kDa precursor protein, such as exonic splicing enhancers (ESEs) were mostly which is subsequently processed into a 64- to 66-kDa identified in individual cases (Schaal and Maniatis mature form and a 22- to 24-kDa cleavage fragment (van 1999; Black 2003; Faustino and Cooper 2003). Analy- der Spoel et al. 2000). Comparative studies carried out sis of candidate sequences demonstrated that purine- on human, mouse, and bovine GLB1 revealed that the rich motifs (GGAGA/GGGA/AGAGA) and CA-rich con- released 22- to 24-kDa proteolytic fragment remains as- sensus motifs (C)CACC(C) are frequently used as splicing sociated to the 64- to 66-kDa chain to form the catalyti- enhancer elements (Du et al. 1997; Liu et al. 1998; Romano et al. 2002; Miriami et al. 2003; Fairbrother et al. 2004). In a previous study we reported clinical and pathologi- 1Corresponding author: Department for Animal Breeding and Genet- ics, University of Veterinary Medicine, Bu¨nteweg 17p, 30559 Hann- cal findings in Alaskan huskies with GM1 -gangliosidosis over, Germany. E-mail: [email protected] (Mu¨ller et al. 1998, 2001). The objective of the present Genetics 170: 1857–1861 ( August 2005) 1858 R. Kreutzer et al. study was to identify the causative genetic defect. There- quenced to confirm their identity. The sequencing reactions fore, the GLB1 gene and GLB1 mRNA processing were were performed by MWG Biotech (Ebersberg, Germany). RNA analysis: Mutation analysis of the whole coding region investigated in a family of Alaskan huskies with GM1 - of the canine GLB1 cDNA was performed on total RNA isolated gangliosidosis. from canine skin fibroblasts using TRIzol Reagent (Invitrogen, Carlsbad, CA). The SMART-RACE method (Clontech, Palo Alto, CA) was used for cDNA synthesis. For first-strand cDNA MATERIALS AND METHODS synthesis 100 ng total RNA and SuperScript II reverse tran- scriptase (Invitrogen) were used. Second-strand synthesis was Animals: A large pedigree of Alaskan huskies segregating performed using 10 ␮l first-strand cDNA and Advantage GC for GM1 -gangliosidosis was available (Mu¨ller et al. 2001). PCR polymerase mix (Clontech). The double-stranded cDNA Affected and related heterozygous carrier animals previously obtained was purified with the QIAquick PCR purification classified by clinical, biochemical, and pathological investiga- kit (QIAGEN, Hilden, Germany). In subsequent 25-␮l PCR tions were used for nucleic acid isolation (Figure 1). RNA reactions 100 ng double-stranded cDNA, primers Ex1_F and from DH82 cells (ATCC CRL-10389) and canine primary skin Ex16_R (Table 1), and the KOD Hot Start polymerase were fibroblasts from two healthy control dogs (Airedale terrier C 1 used. The resulting RT-PCR products were cloned and se- and dachshund C 2) were used as controls in RT-PCR experi- quenced (two independent clones each) or directly se- ments. quenced. DNA analysis: Genomic DNA was isolated from canine skin Sequence analysis and bioinformatics: Sequences were as- fibroblast cell cultures using the Puregene kit (Biozym, Ger- sembled and analyzed for mutations with Sequencher 4.2 many). All enzymatic reactions were carried out in a DNA (Genecodes, Ann Arbor, MI). To predict the possible localiza- programmable thermal controller (PTC-200; MJ Research, tion of SR-protein-specific putative ESEs, a web-based tool, the Cambridge, MA). PCR reactions were performed using prim- ESEfinder Release 2.0, was used (http://rulai.cshl.edu/tools/ ers Ex15_F and Ex15_R (Table 1) and the KOD Hot Start ESE/). The default threshold values were set as the median DNA polymerase (Novagen, Darmstadt, Germany). The PCR of the highest score for each sequence in a set of 30 randomly amplifies a 182-bp product within exon 15 of the GLB1 gene chosen 20-nucleotide sequences previously used for functional (Table 1). The resulting PCR products were cloned and se- SELEX (Cartegni et al. 2003). RESULTS At the beginning of the study a large pedigree of Alaskan huskies segregating for GM1 -gangliosidosis was available (Figure 1A). We had previously measured the biochemical activity of GLB1 in these dogs, which con- firmed that the affected dogs had very little GLB1 activity (Mu¨ller et al. 1998, 2001). Therefore, we started to investigate whether mutations in the GLB1 gene are causative for this defect. We amplified full-length cDNAs from dogs with the three different postulated genotypes Figure 1.—Animals and results of the mutation analysis. (A) Alaskan husky pedigree used in this study (modified from Mu¨ller et al. 2001). (B) RT-PCR amplification of the complete coding region of GLB1 mRNAs with primers Ex1_F and Ex16_R. Samples are numbered according to the pedigree in A. The sizes of the RT-PCR products are indicated beneath the lanes. Note that in the heterozygous dog (1) three different mRNA species are expressed. The agarose gel does not resolve the 2052-bp and the 2071-bp bands; however, several clones from each band were sequenced to confirm the data. M, 250- bp ladder. (C) Mutation analysis of exon 15 on mRNA. Primers Ex15_F and Ex15_R were used for RT-PCR to detect the 19- bp duplication on the mRNA/cDNA level. The presence of the 19-bp duplication in exon 15 of the GLB1 gene leads to a 202-bp product while the wild-type product is only 183 bp. M, 100-bp ladder; neg., negative control without cDNA; DH, DH82 cells from a normal dog; C 1 and C 2, normal control dogs. (D) Mutation analysis on genomic DNA. PCR was again performed with primers Ex15_F and Ex15_R on genomic DNA. C 1, normal control animal; M, 100-bp ladder. (E) Sche- matic of the 19-bp duplication in exon 15 of the canine GLB1 gene that leads to GM1 -gangliosidosis in Alaskan huskies. The position of the diagnostic PCR primers Ex15_F and Ex15_R for this mutation is indicated. Canine GLB1 Mutation 1859 TABLE 1 Primers used for amplification of canine GLB1 fragments Product Ј Ј a Primer Nucleotide sequence (5 -3 ) Position size (bp) TM Ex15_F AAC ACT GAG GAT GCA GTA CGC AGC ϩ1546–ϩ1569 183 68Њ Ex15_R TCC AGG AAA CTG GAT AAA GGT GTC ϩ1705–ϩ1728 Ex1_F AGG GAC GTG GCG ACG GCG ATG Ϫ18–ϩ3 2052 68Њ Ex16_R ACT CCA ACG GGT CAC AGT GTT TC 2012–2034 a ϩ1 corresponds to the adenosine of the translation start codon.
Load more

Recommended publications
  • Epidemiology of Mucopolysaccharidoses Update
    diagnostics Review Epidemiology of Mucopolysaccharidoses Update Betul Celik 1,2 , Saori C. Tomatsu 2 , Shunji Tomatsu 1 and Shaukat A. Khan 1,* 1 Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA; [email protected] (B.C.); [email protected] (S.T.) 2 Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA; [email protected] * Correspondence: [email protected]; Tel.: +302-298-7335; Fax: +302-651-6888 Abstract: Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by a lysosomal enzyme deficiency or malfunction, which leads to the accumulation of glycosaminoglycans in tissues and organs. If not treated at an early stage, patients have various health problems, affecting their quality of life and life-span. Two therapeutic options for MPS are widely used in practice: enzyme replacement therapy and hematopoietic stem cell transplantation. However, early diagnosis of MPS is crucial, as treatment may be too late to reverse or ameliorate the disease progress. It has been noted that the prevalence of MPS and each subtype varies based on geographic regions and/or ethnic background. Each type of MPS is caused by a wide range of the mutational spectrum, mainly missense mutations. Some mutations were derived from the common founder effect. In the previous study, Khan et al. 2018 have reported the epidemiology of MPS from 22 countries and 16 regions. In this study, we aimed to update the prevalence of MPS across the world. We have collected and investigated 189 publications related to the prevalence of MPS via PubMed as of December 2020. In total, data from 33 countries and 23 regions were compiled and analyzed.
    [Show full text]
  • Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma
    cancers Article Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma 1, 1, 1 1 1 Lan Wang y, Anudeep Yekula y, Koushik Muralidharan , Julia L. Small , Zachary S. Rosh , Keiko M. Kang 1,2, Bob S. Carter 1,* and Leonora Balaj 1,* 1 Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA; [email protected] (L.W.); [email protected] (A.Y.); [email protected] (K.M.); [email protected] (J.L.S.); [email protected] (Z.S.R.); [email protected] (K.M.K.) 2 School of Medicine, University of California San Diego, San Diego, CA 92092, USA * Correspondence: [email protected] (B.S.C.); [email protected] (L.B.) These authors contributed equally. y Received: 11 March 2020; Accepted: 7 May 2020; Published: 13 May 2020 Abstract: Sequencing studies have provided novel insights into the heterogeneous molecular landscape of glioblastoma (GBM), unveiling a subset of patients with gene fusions. Tissue biopsy is highly invasive, limited by sampling frequency and incompletely representative of intra-tumor heterogeneity. Extracellular vesicle-based liquid biopsy provides a minimally invasive alternative to diagnose and monitor tumor-specific molecular aberrations in patient biofluids. Here, we used targeted RNA sequencing to screen GBM tissue and the matched plasma of patients (n = 9) for RNA fusion transcripts. We identified two novel fusion transcripts in GBM tissue and five novel fusions in the matched plasma of GBM patients. The fusion transcripts FGFR3-TACC3 and VTI1A-TCF7L2 were detected in both tissue and matched plasma.
    [Show full text]
  • Vacuolated Lymphocytes, a Clinical Finding in GM1 Gangliosidosis
    Vacuolated lymphocytes, a clinical finding in GM1 gangliosidosis Linfocitos vacuolados, un hallazgo clínico en la gangliosidosis GM1 10.20960/revmedlab.00018 00018 Caso clínico Vacuolated lymphocytes, a clinical finding in GM1 gangliosidosis Linfocitos vacuolados, un hallazgo clínico en la gangliosidosis GM1 Silvia Montolio Breva1, Rafael Sánchez Parrilla1, Cristina Gutiérrez Fornes1, and María Teresa Sans Mateu2 1Laboratori Clínic ICS Camp de Tarragona. Terres de l’Ebre. Hospital Universitari Joan XXIII. Tarragona, Spain. 2Direcció Clínica Laboratoris ICS Camp de Tarragona. Terres de l'Ebre, Tarragona. Spain Received: 06/04/2020 Accepted: 08/05/2020 Correspondence: Silvia Montolio Breva. Laboratori Clínic ICS Camp de Tarragona. Terres de l’Ebre. Hospital Universitari Joan XXIII. C/ Dr. Mallafrè Guasch, 4, 43005 Tarragona e-mail: [email protected] Conflicts of interest: The authors declare no conflicts of interests. CASE REPORT A 7-month-old infant was brought to the emergency department of our hospital with fever and respiratory distress accompanied by cough and nasal mucus. After clinical assessment, the diagnostic orientation was compatible with pneumonia. Apart from these common symptoms, there were several clinical signs worth mentioning. On physical examination, cherry-red spots were observed all over the thorax, as well as, hypospadias. The results of complementary tests (cranial radiography, abdominal sonography…) also confirmed macrocephaly, hypotonia, ecchymosis and hepatosplenomegaly. Biochemical analysis showed a remarkable increase in the following parameters: Aspartate amino transferase (AST) 114 UI/L (VR: 5-34 UI/L), lactate dehydrogenase (LDH) 1941 UI/L (VR: 120-246 UI/L) and alkaline phosphatase (ALP) 1632 UI/L (VR: 46-116 UI/L).
    [Show full text]
  • GM1 Gangliosidosis and Morquio B Disease
    Review Article Journal of Genetic Medicine J Genet Med 2021;18(1):16-23 JGM https://doi.org/10.5734/JGM.2021.18.1.16 ISSN 1226-1769 (Print) 2383-8442 (Online) GLB1-related disorders: GM1 gangliosidosis and Morquio B disease Sung Yoon Cho and Dong-Kyu Jin* Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea GLB1-related disorders comprise two phenotypically unique disorders: GM1 gangliosidosis and Morquio B disease. These autosomal recessive disorders are caused by b-galactosidase deficiency. A hallmark of GM1 gangliosidosis is central nervous system degeneration where ganglioside synthesis is highest. The accumulation of keratan sulfate is the suspected cause of the bone findings in Morquio B disease. GM1 gangliosidosis is clinically characterized by a neurodegenerative disorder associat- ed with dysostosis multiplex, while Morquio B disease is characterized by severe skeletal manifestations and the preservation of intelligence. Morquio B disease and GM1 gangliosidosis may be on a continuum of skeletal involvement. There is currently no effective treatment for GLB1-related disorders. Recently, multiple interventions have been developed and there are several ongoing clinical trials. Key words: GM1 gangliosidosis, Mucopolysaccharidoses IVB, Morquio B disease, Beta-galactosidase, GLB1. Introduction ganglioside synthesis is highest. Keratan sulfate accumulation is the suspected causative agent for the bone findings associ- GLB1-related disorders comprise two phenotypically unique ated with Morquio B disease. This review focused on the clinical, disorders, GM1 gangliosidosis (MIM 230500) and Morquio radiographic, and genetic characteristics of these two disorders B disease (mucopolysaccharidosis type IVB, MPS IVB, MIM and introduced recent clinical trials on GLB1-related disorders.
    [Show full text]
  • Revealing the Action Mechanisms of Dexamethasone on the Birth Weight
    ® Observational Study Medicine OPEN Revealing the action mechanisms of dexamethasone on the birth weight of infant using RNA-sequencing data of trophoblast cells ∗ Hongkai Shang, MDa, Liping Sun, BMa, Thorsten Braun, MDb, Qi Si, BMa, Jinyi Tong, MMa, Abstract Dexamethasone (DEX) could induce low birth weight of infant, and low birth weight has close associations with glucocorticoid levels, insulin resistance, hypertension, and metabolic syndrome in adulthood. This study was designed to reveal the action mechanisms of DEX on the birth weight of infant. Using quantitative real-time polymerase chain reaction (qRT-PCR), trophoblast cells of human placenta were identified and the optimum treatment time of DEX were determined. Trophoblast cells were treated by DEX (DEX group) or ethanol (control group) (each group had 3 samples), and then were performed with RNA-sequencing. Afterward, the differentially expressed genes (DEGs) were identified by R package, and their potential functions were successively enriched using DAVID database and Enrichr method. Followed by protein–protein interaction (PPI) network was constructed using Cytoscape software. Using Enrichr method and TargetScan software, the transcription factors (TFs) and micorRNAs (miRNAs) targeted the DEGs separately were predicted. Based on MsigDB database, gene set enrichment analysis (GSEA) was performed. There were 391 DEGs screened from the DEX group. Upregulated SRR and potassium voltage-gated channel subfamily J member 4(KCNJ4) and downregulated GALNT1 separately were enriched in PDZ (an acronym of PSD-95, Dlg, and ZO-1) domain binding and Mucin type O-glycan biosynthesis. In the PPI network, CDK2 and CDK4 had higher degrees. TFs ATF2 and E2F4 and miRNA miR-16 were predicted for the DEGs.
    [Show full text]
  • Clinica Chimica Acta 436 (2014) 112–120
    Clinica Chimica Acta 436 (2014) 112–120 Contents lists available at ScienceDirect Clinica Chimica Acta journal homepage: www.elsevier.com/locate/clinchim Molecular characteristics of patients with glycosaminoglycan storage disorders in Russia Dimitry A. Chistiakov a,b,⁎,KirillV.Savost'anovb, Lyudmila M. Kuzenkova c, Anait K. Gevorkyan d, Alexander A. Pushkov b,AlexeyG.Nikitinb, Alexander V. Pakhomov b,NatoD.Vashakmadzec, Natalia V. Zhurkova b, Tatiana V. Podkletnova c, Nikolai A. Mayansky e, Leila S. Namazova-Baranova d, Alexander A. Baranov f a Department of Medical Nanobiotechnology, Pirogov Russian State Medical University, 117997 Moscow, Russia b Department of Molecular Genetic Diagnostics, Division of Laboratory Medicine, Institute of Pediatrics, Research Center for Children's Health, 119991 Moscow, Russia c Department of Psychoneurology and Psychosomatic Pathology, Institute of Pediatrics, Research Center for Children's Health, 119991 Moscow, Russia d Institute of Preventive Pediatrics and Rehabilitation, Research Center for Children's Health, 119991 Moscow, Russia e Department of Experimental Immunology and Virology, Division of Laboratory Medicine, Institute of Pediatrics, Research Center for Children's Health, 119991 Moscow, Russia f Research Center for Children's Health, 119991 Moscow, Russia article info abstract Article history: Background: The mucopolysaccharidoses (MPSs) are rare genetic disorders caused by mutations in lysosomal Received 3 May 2014 enzymes involved in the degradation of glycosaminoglycans (GAGs). In this study, we analyzed a total of 48 Received in revised form 16 May 2014 patients including MPSI (n = 6), MPSII (n = 18), MPSIIIA (n = 11), MPSIVA (n = 3), and MPSVI (n = 10). Accepted 18 May 2014 Methods: In MPS patients, urinary GAGs were colorimetrically assayed.
    [Show full text]
  • Disorders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses
    551 38 Disorders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses Marie T. Vanier, Catherine Caillaud, Thierry Levade 38.1 Disorders of Sphingolipid Synthesis – 553 38.2 Sphingolipidoses – 556 38.3 Niemann-Pick Disease Type C – 566 38.4 Neuronal Ceroid Lipofuscinoses – 568 References – 571 J.-M. Saudubray et al. (Eds.), Inborn Metabolic Diseases, DOI 10.1007/978-3-662-49771-5_ 38 , © Springer-Verlag Berlin Heidelberg 2016 552 Chapter 38 · Disor ders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses O C 22:0 (Fatty acid) Ganglio- series a series b HN OH Sphingosine (Sphingoid base) OH βββ β βββ β Typical Ceramide (Cer) -Cer -Cer GD1a GT1b Glc ββββ βββ β Gal -Cer -Cer Globo-series GalNAc GM1a GD1b Neu5Ac βαββ -Cer Gb4 ββ β ββ β -Cer -Cer αβ β -Cer GM2 GD2 Sphingomyelin Pcholine-Cer Gb3 B4GALNT1 [SPG46] [SPG26] β β β ββ ββ CERS1-6 GBA2 -Cer -Cer ST3GAL5 -Cer -Cer So1P So Cer GM3 GD3 GlcCer - LacCer UDP-Glc UDP Gal CMP -Neu5Ac - UDP Gal PAPS Glycosphingolipids GalCer Sulfatide ββ Dihydro -Cer -Cer SO 4 Golgi Ceramide apparatus 2-OH- 2-OH-FA Acyl-CoA FA2H CERS1-6 [SPG35] CYP4F22 ω-OH- ω-OH- FA Acyl-CoA ULCFA ULCFA-CoA ULCFA GM1, GM2, GM3: monosialo- Sphinganine gangliosides Endoplasmic GD3, GD2, GD1a, GD1b: disialo-gangliosides reticulum KetoSphinganine GT1b: trisialoganglioside SPTLC1/2 [HSAN1] N-acetyl-neuraminic acid: sialic acid found in normal human cells Palmitoyl-CoA Deoxy-sphinganine + Serine +Ala or Gly Deoxymethylsphinganine 38 . Fig. 38.1 Schematic representation of the structure of the main sphingolipids , and their biosynthetic pathways.
    [Show full text]
  • Metabolic Network-Based Stratification of Hepatocellular Carcinoma Reveals Three Distinct Tumor Subtypes
    Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes Gholamreza Bidkhoria,b,1, Rui Benfeitasa,1, Martina Klevstigc,d, Cheng Zhanga, Jens Nielsene, Mathias Uhlena, Jan Borenc,d, and Adil Mardinoglua,b,e,2 aScience for Life Laboratory, KTH Royal Institute of Technology, SE-17121 Stockholm, Sweden; bCentre for Host-Microbiome Interactions, Dental Institute, King’s College London, SE1 9RT London, United Kingdom; cDepartment of Molecular and Clinical Medicine, University of Gothenburg, SE-41345 Gothenburg, Sweden; dThe Wallenberg Laboratory, Sahlgrenska University Hospital, SE-41345 Gothenburg, Sweden; and eDepartment of Biology and Biological Engineering, Chalmers University of Technology, SE-41296 Gothenburg, Sweden Edited by Sang Yup Lee, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, and approved November 1, 2018 (received for review April 27, 2018) Hepatocellular carcinoma (HCC) is one of the most frequent forms of of markers associated with recurrence and poor prognosis (13–15). liver cancer, and effective treatment methods are limited due to Moreover, genome-scale metabolic models (GEMs), collections tumor heterogeneity. There is a great need for comprehensive of biochemical reactions, and associated enzymes and transporters approaches to stratify HCC patients, gain biological insights into have been successfully used to characterize the metabolism of subtypes, and ultimately identify effective therapeutic targets. We HCC, as well as identify drug targets for HCC patients (11, 16–18). stratified HCC patients and characterized each subtype using tran- For instance, HCC tumors have been stratified based on the uti- scriptomics data, genome-scale metabolic networks and network lization of acetate (11). Analysis of HCC metabolism has also led topology/controllability analysis.
    [Show full text]
  • Transforming Growth Factor ß1-Mediated Functional Inhibition Of
    Myelodysplastic Syndromes SUPPLEMENTARY APPENDIX Transforming growth factor 1- mediated functional inhibition of mesenchymal stromal celβls in myelodysplastic syndromes and acute myeloid leukemia Stefanie Geyh, 1* Manuel Rodríguez-Paredes, 1,2 * Paul Jäger, 1 Annemarie Koch, 1 Felix Bormann, 2 Julian Gutekunst, 2 Christoph Zilkens, 3 Ulrich Germing, 1 Guido Kobbe, 1 Frank Lyko, 2 Rainer Haas 1 and Thomas Schroeder 1 1Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Medical Faculty; 2Division of Epigenetics, DKFZ- ZMBH Alliance, German Cancer Research Center, Heidelberg and 3Department of Orthopedic Surgery, University of Duesseldorf, Medical Faculty, Germany *SG and MR-P contributed equally to this work. ©2018 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2017.186734 Received: December 19, 2017. Accepted: May 14, 2018. Pre-published: May 17, 2018. Correspondence: [email protected] Figure S1 Downregulated genes Downregulated genes Upregulated Figure S1. Heatmaps showing the 50 most upregulated and downregulated genes between the 3 healthy MSC controls and the 9 RCMD-, RAEB- and AML-derived MSC samples. Color scale depicts the rlog-transformed FPKM values for each gene and every sample. Figure S2 Downregulated genes Downregulated genes Upregulated Figure S2. Heatmaps showing the 50 most upregulated and downregulated genes between the 3 healthy MSC controls and the 3 RCMD, RAEB and AML MSC samples, respectively. Color scales depict the rlog-transformed FPKM values for each gene and every sample. Figure S3 A. B. 0.0015 *** ** <-3 -2 0.0010 RCMD RAEB AML -1 0 1 0.0005 Log2FC LTF 2 CCL26/GAPDH INHBB >3 0.0000 TGFB2 y S h D ML M A ealt ll LTF H a EGF 0.003 *** ** INHBB TGFB2 0.002 INHBB IGFBP7 0.001 GDF11 LIF/GAPDH BMP1 0.000 y L th M TNFSF12 l A FGF13 ea ll MDS H a FGF13 0.0015 * TNFSF10 TNFSF10 0.0010 0.0005 SPP1/GAPDH 0.0000 y th l AML ea H all MDS Figure S3.
    [Show full text]
  • Storage Disorders
    GENETIC TESTING SOLUTIONS FOR: STORAGE DISORDERS EGL Genetics has nearly 50 years of genetic testing history built upon a strong academic foundation. Our expertise spans common and rare genetic disease testing, genomic variant interpretation, test development and research. As we have grown, we have evolved into a high-science and high-performing CLIA-certifi ed and CAP-accredited laboratory with over 1,100 test offerings across biochemical genetics, cytogenetics, and molecular genetic testing. COMPREHENSIVE OFFERINGS Lysosomal storage disorders and glycogen storage disorders (GSDs) with numerous subtypes, wide-ranging phenotypes and multi-organ and system involvement, which are often impossible to diagnose based on clinical features alone. EGL Genetics offers disease-specifi c, as well as, comprehensive biochemical and molecular testing to pinpoint the underlying cause of symptoms. Identifi cation of a causative genetic defect may provide information for prognosis and therapeutic intervention, and is required for carrier testing and early prenatal diagnosis. Lysosomal Storage Disorders • Mucopolysaccharidoses • Sphingolipidoses • Oligosaccharidoses Glycogen Storage Disorders ADVANTAGES OF PARTNERING WITH EGL GENETICS: • Board-certifi ed laboratory directors & genetic counselors to answer clinical and analytical questions • EGL Genetics’ oligosaccharide screening method provides additional information and more targeted follow-up pathways than traditional qualitative screens • Customizable NGS panels with add-on genes available upon request
    [Show full text]
  • Perkinelmer Genomics to Request the Saliva Swab Collection Kit for Patients That Cannot Provide a Blood Sample As Whole Blood Is the Preferred Sample
    Comprehensive Mucopoly- saccharidoses (MPS) Panel Test Code D4502 Test Summary This test analyzes 23 genes that have been associated with mucopolysaccharidoses (MPS). Turn-Around-Time (TAT)* 3 - 5 weeks Acceptable Sample Types Whole Blood (EDTA) (Preferred sample type) DNA, Isolated Dried Blood Spots Saliva Acceptable Billing Types Self (patient) Payment Institutional Billing Commercial Insurance Indications for Testing This panel may be appropriate for individuals with a clinical suspicion of a mucopolysaccharidoses and/or a family history of mucopolysaccharidoses. Test Description This panel analyzes 23 genes that have been associated with mucopolysaccharidoses (MPS). Both sequencing and deletion/duplication (CNV) analysis will be performed on the coding regions of all genes included (unless otherwise marked). All analysis is performed utilizing Next Generation Sequencing (NGS) technology. CNV analysis is designed to detect the majority of deletions and duplications of three exons or greater in size. Smaller CNV events may also be detected and reported, but additional follow-up testing is recommended if a smaller CNV is suspected. All variants are classified according to ACMG guidelines. Condition Description Mucopolysaccharidoses (MPS) is a group of lysosomal storage disorders caused from the absence of, or insufficient levels, of enzymes needed to break down mucopolysaccharides. Symptoms may include coarse facial features, progressive cognitive disability, inguinal and/or umbilical hernias, hepatosplenomegaly, cardiac valve dysfunction, recurrent ear and respiratory infections, corneal clouding and skeletal deformities. The prevelance of MPS disorders collectively is about 1/25,000. Genes AGA, ARSB, CTSA, CTSK, FUCA1, GALNS, GLB1, GNPTAB, GNPTG, GNS, GUSB, HGSNAT, HYAL1, IDS, IDUA, MAN2B1, MANBA, MCOLN1, NAGA, NAGLU, NEU1, SGSH, SLC17A5 Test Methods and Limitations Sequencing is performed on genomic DNA using an Agilent targeted sequence capture method to enrich for the genes on this panel.
    [Show full text]
  • D835a621d460bc7f1f92f1be9b4
    International Journal of Molecular Sciences Review Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses Juan Camilo Losada Díaz 1, Jacobo Cepeda del Castillo 1, Edwin Alexander Rodriguez-López 1,2 and Carlos J. Alméciga-Díaz 1,* 1 Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá D.C. 110231, Colombia; [email protected] (J.C.L.D.); [email protected] (J.C.d.C.); [email protected] (E.A.R.-L.) 2 Chemistry Department, Faculty of Science, Pontificia Universidad Javeriana, Bogotá D.C. 110231, Colombia * Correspondence: [email protected]; Tel.: +57-1-3208320 (ext. 4140); Fax: +57-1-3208320 (ext. 4099) Received: 30 October 2019; Accepted: 25 November 2019; Published: 29 December 2019 Abstract: The mucopolysaccharidoses (MPS) are a group of 11 lysosomal storage diseases (LSDs) produced by mutations in the enzymes involved in the lysosomal catabolism of glycosaminoglycans. Most of the mutations affecting these enzymes may lead to changes in processing, folding, glycosylation, pH stability, protein aggregation, and defective transport to the lysosomes. It this sense, it has been proposed that the use of small molecules, called pharmacological chaperones (PCs), can restore the folding, trafficking, and biological activity of mutated enzymes. PCs have the advantages of wide tissue distribution, potential oral administration, lower production cost, and fewer issues of immunogenicity than enzyme replacement therapy. In this paper, we will review the advances in the identification and characterization of PCs for the MPS. These molecules have been described for MPS II, IVA, and IVB, showing a mutation-dependent enhancement of the mutated enzymes.
    [Show full text]